Literature DB >> 32203683

Sinonasal papillomas: A single centre experience on 137 cases with emphasis on malignant transformation and EGFR/KRAS status in "carcinoma ex papilloma".

Saskia Maisch1, Sarina K Mueller2, Maximilian Traxdorf2, Veronika Weyerer1, Robert Stoehr1, Heinrich Iro2, Arndt Hartmann1, Abbas Agaimy3.   

Abstract

Among the three major histological subtypes of sinonasal papillomas, inverted (ISP) and oncocytic (OSP) sinonasal papillomas tend to undergo malignant transformation to carcinoma. However, criteria determining risk of recurrence and malignant progression have not been established. Recently, EGFR and KRAS mutations were detected to be characteristic for ISP and OSP, respectively. In this study, we analyzed 137 sinonasal papilloma cases (132 ISP and 5 OSP) for clinicopathological characteristics, frequency of recurrences/malignant transformation, and histological types and genetic features of carcinoma ex Schneiderian papilloma. OSP presented at a higher age than ISP (median, 75 vs. 57 years) and affected predominantly females. Overall frequency of recurrences and malignant transformation was 23.1% and 9.5%, respectively. Rates of recurrence (33.3% vs. 22.0%) and malignant transformation (33.3% vs. 8.8%) were higher in OSP compared to ISP, respectively. Carcinomas (n = 10) occurred mostly synchronously, more frequently in females and mainly associated with ISP (n = 9). Squamous cell carcinoma (SCC) was the most frequently associated malignancy. Concordant EGFR (in ISP/associated carcinoma) and KRAS (in the OSP/associated carcinoma) mutations were detected in all successfully analyzed matching papilloma/carcinoma pairs, confirming their shared clonal origin. Results of this large study are in line with recent studies showing frequent EGFR and KRAS mutations in sinonasal carcinoma ex Schneiderian papilloma. As the papilloma component might on occasion be missed on biopsy of synchronous carcinoma ex papilloma, EGFR and KRAS mutation testing represents a promising molecular surrogate for sinonasal "carcinoma ex papilloma", at the same time offering an opportunity for targeting mutant EGFR in this rare cancer type.
Copyright © 2020 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Carcinoma ex papilloma; EGFR; Inverted papilloma; KRAS; Oncocytic papilloma; Schneiderian papilloma; Sinonasal papilloma; Squamous cell carcinoma

Mesh:

Substances:

Year:  2020        PMID: 32203683     DOI: 10.1016/j.anndiagpath.2020.151504

Source DB:  PubMed          Journal:  Ann Diagn Pathol        ISSN: 1092-9134            Impact factor:   2.090


  4 in total

Review 1.  Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Nasal Cavity, Paranasal Sinuses and Skull Base.

Authors:  Lester D R Thompson; Justin A Bishop
Journal:  Head Neck Pathol       Date:  2022-03-21

Review 2.  Sinonasal Inverted Papilloma and Squamous Cell Carcinoma: Contemporary Management and Patient Outcomes.

Authors:  Jacob G Eide; Kevin C Welch; Nithin D Adappa; James N Palmer; Charles C L Tong
Journal:  Cancers (Basel)       Date:  2022-04-28       Impact factor: 6.575

3.  IMP3 Immunohistochemical Expression in Inverted Papilloma and Inverted Papilloma-Associated Sinonasal Squamous Cell Carcinoma.

Authors:  Sarah A Hakim; Nermine M Abd Raboh; Lobna S Shash
Journal:  Anal Cell Pathol (Amst)       Date:  2021-02-16       Impact factor: 2.916

Review 4.  EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma.

Authors:  Laura Pacini; Virginia N Cabal; Mario A Hermsen; Paul H Huang
Journal:  Cancers (Basel)       Date:  2022-01-13       Impact factor: 6.639

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.